Prostate cancer is one of the most common cancers in men. The standard treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) have been assessed but failed to improve the overall survival (OS). Currently, novel treatment methods such as the targeted antibody-drug conjugates (ADCs) have been found to significantly improve the progression-free survival and OS rates.
